Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2863479 | The American Journal of the Medical Sciences | 2014 | 9 Pages |
Abstract
Many theories and clinical trials have attempted to address the effect of low-density lipoprotein (LDL) lowering in chronic congestive heart failure (CHF). The current evidence suggests that there is no convincing reason for administering statins to patients with nonischemic heart failure. Although they do not reduce the mortality rate, statins reduce LDL cholesterol and may provide some benefit to patients with ischemic heart failure. in contrast, some authors believe that statin therapy may actually worsen outcomes in patients with CHF, especially if there is excessive reduction in LDL cholesterol. This review discusses the theories attempting to link the adverse effects of statin-mediated LDL lowering in CHF to increased levels of endotoxin or reduced levels of coenzyme Q10. In addition, the 2 largest randomized, double-blind, placebo-controlled clinical trials (CoRoNA and Gissi-HF) were discussed. it is clear that more trials are needed to definitely ascertain the effect of statins on CHF.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Constantine E. MD, PhD, Hassan MD, Mohammed MD, Gabriel MD, Timothy J. MS, MD, Mark R. MD, Kathleen M. MSN, ANP,